about
Dipeptidyl peptidase-4 (DPP-4) inhibition with linagliptin reduces western diet-induced myocardial TRAF3IP2 expression, inflammation and fibrosis in female miceThe burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0 mg.Potent long-acting rhFGF21 analog for treatment of diabetic nephropathy in db/db and DIO miceVertical sleeve gastrectomy reduces blood pressure and hypothalamic endoplasmic reticulum stress in mice.Future challenges and therapeutic opportunities in type 2 diabetes: Changing the paradigm of current therapyGlucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain-Adipocyte Axis.Cardiovascular inflammation is reduced with methotrexate in diabetes.Cardiovascular safety and benefits of GLP-1 receptor agonists.Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor.Glucagon-like peptide-1 (GLP-1) mediates cardioprotection by remote ischaemic conditioning.Intestinal lymphatic vasculature: structure, mechanisms and functions.Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein.Glucagon-like peptide-1 elicits vasodilation in adipose tissue and skeletal muscle in healthy men.Obestatin regulates cardiovascular function and promotes cardioprotection through the nitric oxide pathway.The autonomic nervous system and cardiac GLP-1 receptors control heart rate in mice.Semaglutide seems to be more effective the other GLP-1Ras.Bile acids at the cross-roads of gut microbiome-host cardiometabolic interactions.Cardioprotective anti-hyperglycaemic medications: a review of clinical trials.Discovery, characterization, and clinical development of the glucagon-like peptides.The current state of GPCR-based drug discovery to treat metabolic disease.Major adverse cardiovascular event reduction with GLP-1 and SGLT2 agents: evidence and clinical potential.Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm.Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?Postmeal increment in intact glucagon-like peptide 1 level, but not intact glucose-dependent insulinotropic polypeptide levels, is inversely associated with metabolic syndrome in patients with type 2 diabetes.Incretin secretion in humans is under the influence of cannabinoid receptors.Real-world clinical outcomes and predictors of glycaemic and weight response to exenatide once weekly in patients with type 2 diabetes: The CIBELES project.Advances in micro- and nanotechnologies for the GLP-1-based therapy and imaging of pancreatic beta-cells.Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms.Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA Adverse Event Reporting System.GLP-1 receptor expression within the human heart.Teneligliptin enhances the beneficial effects of GLP-1 in endothelial cells exposed to hyperglycemic conditions.[Why is a combination of basal insulin with a GLP-1 receptor agonist useful in many patients with type 2 diabetes?]The effect of liraglutide on renal function: A randomized clinical trial.ZP2495 Protects against Myocardial Ischemia/Reperfusion Injury in Diabetic Mice through Improvement of Cardiac Metabolism and Mitochondrial Function: The Possible Involvement of AMPK-FoxO3a Signal Pathway.A New Treatment Strategy for Parkinson's Disease through the Gut-Brain Axis: The Glucagon-Like Peptide-1 Receptor Pathway.Conditional and Reversible Activation of Class A and B G Protein-Coupled Receptors Using Tethered Pharmacology.The role of dipeptidylpeptidase-4 inhibitors in management of cardiovascular disease in diabetes; focus on linagliptin.[Cardiovascular aspects of diabetes treatment : Finally a reason for cardiologists to be pleased].The incretin hormone GIP is upregulated in patients with atherosclerosis and stabilizes plaques in ApoE-/- mice by blocking monocyte/macrophage activation.MEDI0382, a GLP-1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomized, Phase 1 study
P2860
Q33644666-F850FD52-5419-4A0D-B3C1-51198B4FC192Q33750634-88547136-22D4-4AFD-96CF-90722C3D692DQ33869232-3A385716-5B72-4697-8B3C-0B5995C3CD97Q37731183-0439089E-644F-47F6-9524-216D350445ABQ38692092-3D164BA0-71E5-40DB-9692-AA5B169900EDQ38753804-52E2843B-116C-4DA4-BBDC-4975D051390DQ38902200-A9E894B7-8D82-4508-B7BE-542734B042E9Q39013056-F2C909F2-1BF5-4476-B371-122B2D89E73BQ39255963-8D8A531E-87F2-4EEA-B419-A461E3880F4BQ39323549-1C8EDC5B-8014-43F1-8B93-D0989EBBCCD1Q39401415-AA7D2450-3A27-4611-861E-6658333C4432Q41597824-F0EF308D-494F-4AFD-9E77-2B51150F1F4BQ42186713-CEF8E34D-2955-410D-8029-0C0FEEEEAF30Q42512913-51DC5C51-3C0D-4D7A-9DD3-657399B29F08Q46906226-53FFE64D-8234-4B14-A2E1-73A5B05CAC81Q47114286-191FDFDA-87B3-47A3-A5A9-28184E4E9526Q47134180-B8323BEF-4C7A-4477-9AC7-ECB2490722A4Q47297477-B45EBC6A-86AB-4408-87C3-FD17D3F4EE94Q47333882-DD8CCB3A-BF66-4D05-9601-B925663B6180Q47696468-C718FE4C-58DD-4942-AF81-7AA06FABB48AQ47726421-78BAA946-6912-4C48-928F-7E06D02C0B50Q47755876-02560105-27A6-4883-ACD2-782A23D13640Q47849041-5BBE4D6E-CA9C-4224-9B31-7972E1FA6478Q48190264-09F02A13-2BC3-42DE-A0E2-A60084B6C1EEQ48215464-8C9CCF25-1466-4927-8F6C-2617F420095CQ48228283-8FDDFAEE-BFEF-4E5B-BB05-6DAA855F1801Q49630159-C95E950F-D1C2-4A62-9834-9045E2673689Q49833824-D70A92AD-FB96-41D9-9C1B-451E670DF625Q49955687-B3B06889-817D-4424-88E6-7BD48C3B74DDQ49999597-DADCF77C-BE71-4C5F-8C01-14F4329285CCQ50532481-6275BFF0-CE97-4E0B-ABF8-A2B8D46C9019Q51262448-4DB19A9F-69B2-4E80-BE2B-16B8CE4A8ABEQ51381510-07803DFD-FEDE-444E-944A-52128D35FCADQ51731634-3D22B85A-B163-40CB-A875-AE253408A876Q51786227-90652F22-8D71-4A4E-9426-560AB36E1697Q52659149-C81FAE53-24E7-4CEF-BA6C-D5668E91C3EAQ52718518-5C89E2F5-43F9-4942-982B-5AD8525E8103Q53550139-BEDD1D34-56DB-4522-9914-BED117ECDCF0Q55467227-44122DE6-E372-42F6-84D2-A8C4916B1CD1Q56967870-0CD01268-4DCA-4198-B59D-6A70C4B12FAA
P2860
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
The Cardiovascular Biology of Glucagon-like Peptide-1.
@en
type
label
The Cardiovascular Biology of Glucagon-like Peptide-1.
@en
prefLabel
The Cardiovascular Biology of Glucagon-like Peptide-1.
@en
P1433
P1476
The Cardiovascular Biology of Glucagon-like Peptide-1.
@en
P356
10.1016/J.CMET.2016.06.009
P577
2016-06-22T00:00:00Z